Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice.
Today's heart teams already face a number of challenges on a day-to-day basis. New data suggest they could soon be treating more patients than ever before.
The show will go on. After HFSA was forced to cancel its annual meeting due to Hurricane Helene, the group will now be livestreaming a series of late-breaking clinical sessions for anyone who had previously registered.
The news comes just one day before HFSA 2024 was scheduled to begin. HFSA is already considering the possibility of virtual sessions, but its primary concern is the safety of attendees.
In addition to more traditional presentations, this year's meeting will also include "Rapid Fire" sessions designed to pack a lot of late-breaking data into a relatively small amount of time.
The new AUC document, which examines the treatment of both symptomatic and asymptomatic patients, was published in full in the Journal of the American College of Cardiology.
The Heart Failure Society of America and International Society for Heart and Lung Transplantation worked together on the document, hoping their recommendations serve as a "critical roadmap" for clinicians.
